Trial Profile
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Rimiducid (Primary) ; Rivogenlecleucel (Primary)
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Wiskott-Aldrich syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Bellicum Pharmaceuticals
- 22 Sep 2023 Status changed from active, no longer recruiting to discontinued.
- 14 Dec 2021 Results (n=8) assessing outcome of a cohort of children affected by Wiskott-Aldrich Syndrome who received a TBdepl-haploHSCT, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 21 Nov 2020 This trial has been Completed in Italy, according to European Clinical Trials Database record.